title: Safety in simple versus complex stenting of coronary artery bifurcation lesions. The nordic bifurcation study 14-month follow-up results.
abstract: OBJECTIVE
  The risk of stent thrombosis has been reported to increase with percutaneous coronary intervention (PCI) complexity. The present study reports the pre-specified secondary endpoint of a 14-month stent thrombosis and major adverse cardiac events in patients stented with a simple versus a complex bifurcation technique using sirolimus eluting stents (SES).
  
  
  RESULTS
  A total of 413 patients with a coronary bifurcation lesion were randomised to a simple treatment strategy; stenting of main vessel and optional stenting of side branch (MV group), or to a complex stenting strategy; stenting of both main vessel and side branch (MV+SB group). Mortality data were available in all patients and 14-month clinical follow-up data in 395 (96%) of the patients. After 14 months, the rates of definite, probable and possible stent thrombosis (ARC criteria) were 1.0% vs. 0.5%, 1.0% vs. 0% and 0.5% vs. 0% (ns) in the MV and in the MV+SB groups, respectively. Rates of MACE were 9.5% in the MV group and 8.2% in the MV+SB group (ns). Total death was seen in 2.4% vs. 1.0% and non-PCI related myocardial infarction in 2.0% vs. 1.0% in the MV and the MV+SB groups, respectively.
  
  
  CONCLUSIONS
  After 14 months, two months after recommended cessation of dual antiplatelet therapy, the rates of stent thrombosis and major adverse cardiac events were low and independent of treatment complexity in patients treated with SES for coronary artery bifurcation lesions.
authors.affiliation: Department of Cardiology, Gentofte University Hospital, Gentofte, Denmark.
authors.forename: Jan S
authors.initials: JS
authors.lastname: Jensen
authors.forename: Anders
authors.initials: A
authors.lastname: Galløe
authors.forename: Jens F
authors.initials: JF
authors.lastname: Lassen
authors.forename: Andrejs
authors.initials: A
authors.lastname: Erglis
authors.forename: Indulis
authors.initials: I
authors.lastname: Kumsars
authors.forename: Terje K
authors.initials: TK
authors.lastname: Steigen
authors.forename: Rune
authors.initials: R
authors.lastname: Wiseth
authors.forename: Inga
authors.initials: I
authors.lastname: Narbute
authors.forename: Pål
authors.initials: P
authors.lastname: Gunnes
authors.forename: Jan
authors.initials: J
authors.lastname: Mannsverk
authors.forename: Oliver
authors.initials: O
authors.lastname: Meyerdierks
authors.forename: Svein
authors.initials: S
authors.lastname: Rotevatn
authors.forename: Matti
authors.initials: M
authors.lastname: Niemelä
authors.forename: Kari
authors.initials: K
authors.lastname: Kervinen
authors.forename: Kjell
authors.initials: K
authors.lastname: Nikus
authors.forename: Saila
authors.initials: S
authors.lastname: Vikman
authors.forename: Jan
authors.initials: J
authors.lastname: Ravkilde
authors.forename: Stefan
authors.initials: S
authors.lastname: James
authors.forename: Jens
authors.initials: J
authors.lastname: Aarøe
authors.forename: Antti
authors.initials: A
authors.lastname: Ylitalo
authors.forename: Steffen
authors.initials: S
authors.lastname: Helqvist
authors.forename: Iwar
authors.initials: I
authors.lastname: Sjögren
authors.forename: Per
authors.initials: P
authors.lastname: Thayssen
authors.forename: Kari
authors.initials: K
authors.lastname: Virtanen
authors.forename: Mikko
authors.initials: M
authors.lastname: Puhakka
authors.forename: Juhani
authors.initials: J
authors.lastname: Airaksinen
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D003324:Coronary Artery Disease / Q000473:pathology* / Q000628:therapy*; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage; D013927:Thrombosis / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D020123:Sirolimus